All In Biotech

NDA 021968 · Cppi Cv

Sutent

Sunitinib Malate · Oral

Accelerated approvalPriority review

Last checked: Nov 19, 2026Latest source record: Feb 2, 2007 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Jan 26, 2006

Approved uses

5

Original approval plus efficacy supplements

Registered trials

500

58 Phase 3, 25 recruiting

FAERS reports

39,149

30,215 serious, 11,688 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • SUTENT · SUNITINIB MALATE EQ 50MG BASE · CAPSULE, ORAL · Prescription
  • SUTENT · SUNITINIB MALATE EQ 12.5MG BASE · CAPSULE, ORAL · Prescription
  • SUTENT · SUNITINIB MALATE EQ 25MG BASE · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Sunitinib Malate" as an intervention, any sponsor and status, largest first.

All 500 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death7,452
  • diarrhoea4,422
  • fatigue4,195
  • disease progression3,912
  • nausea3,121
  • asthenia2,461
  • decreased appetite2,316
  • vomiting2,211
  • neoplasm progression2,020
  • hypertension1,805
  • dysgeusia1,696
  • weight decreased1,589

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
2006777
2007810
2008838
20091,585
20103,423
20112,736
20123,177
20132,701
20143,143
20153,905
20163,384
20172,986
20182,531
20192,041
20201,594
20211,172
20221,066
2023508
2024314
2025269
2026188

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Sutent (Sunitinib Malate)

2024 spending

$4.6M

Beneficiaries

78

364 claims

Per beneficiary

$59,222

$514.66 per unit

View as table
YearSpending
2020$120,222,574
2021$96,954,410
2022$17,597,961
2023$7,397,129
2024$4,619,328

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 56 on PubMed

Sponsor: Cppi Cv

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.